drugset / Trial / NCT03447990

v4 Study Evaluating the Safety, Tolerability and Preliminary Pharmacokinetics and Pharmacodynamics of MYK-491

NCT03447990

Phase 1/2 Completed 52 enrolled Bristol-Myers Squibb
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this Phase 1b/2a study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of MYK-491 in patients with stable heart failure.

Timeline

Start
2018-02-06
Primary completion
2019-10-24
Completion
2019-10-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Danicamtiv Small molecule Oral